Moleculin Prices $9.3M Public Offering at $2.19/Share, Deepening Dilution
MBRX sits 22% above its 52-week low of $0.8 on elevated volume (2.8× avg).
Summary
Moleculin priced a $9.3 million public offering at $2.19 per share with warrants, following the S-1/A filed yesterday. The offering is highly dilutive given the company's $5.2 million market cap and comes amid a going concern warning and a need for $25 million in capital. This follows positive interim MIRACLE trial data but the financing underscores the cash burn urgency. The stock closed at $0.97, so the offering price represents a premium, but the dilution is severe. The offering was also reported at $0.75 per share in a previous fragment.
Updates
· SEC 424B5 — The offering is a best-efforts deal at $0.75 per share and three common warrants, with insiders buying 1,319,998 shares and 3,959,994 warrants. Net proceeds are estimated at $8.5 million.
At the time of this announcement, MBRX was trading at $0.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.2M. The 52-week trading range was $0.80 to $18.25. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.